Navigation Links
Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
Date:12/11/2009

SAN DIEGO, Dec. 11 /PRNewswire/ -- Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML). AC220 is a novel, orally available, potent and highly selective small molecule that was specifically designed as a FMS-like tyrosine kinase-3 (FLT3) inhibitor. The ACE study is designed to be a pivotal trial that could potentially support a United States regulatory filing for AC220 to address a targeted AML patient population with the internal tandem duplication (ITD) activating mutation for FLT3.

"Based on the promising results of our first-in-human clinical trial presented at the American Society of Hematology (ASH), we are pleased to advance AC220 into this important Phase 2 study in AML. We are deeply grateful to our investigators, their staff, and their patients, as well as our entire team at Ambit, for their vital contributions in achieving this significant milestone," said Wendell Wierenga, EVP of Research and Development at Ambit. "If the ACE study is successful, AC220 could emerge as the first once-a-day, orally available targeted therapy for AML patients. Over the next several months we plan to initiate additional clinical trials with AC220 to support the potential registration in AML, and to explore its utility in certain types of solid tumors."

"AML is a devastating disease for which few treatment options exist," said Jorge Cortes MD, Internist and Professor, Deputy Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, and principal investigator for the ACE Study. "There are no treatments currently approved by the FDA that specifically target the activating ITD mutations of the FLT3 kinase, present in 2
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT
2. YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
3. Cell Biosciences Acquires Protein Forest
4. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
5. Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
6. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
7. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
8. American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
9. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
10. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
11. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Apache Junction, AZ (PRWEB) June 02, 2015 ... of light microscope technology, Yancy Corporation is ... with any desired material and biological sample, displaying the ... and electron bonds between atoms. , Jeff Porter, Co-Founder ... new physics are just that – rare. They come ...
(Date:6/2/2015)... 2, 2015 MGB Biopharma ... resistance problem  MGB Biopharma, a biopharmaceutical ... to address the major global problem of antibiotic ... stable intravenous (IV) formulation of MGB-BP-3, designed for the ... The intravenous formulation of MGB-BP-3 is ...
(Date:6/2/2015)... June 02, 2015 German-based Moenninghoff has ... States distributor for the Moenninghoff product line . ... am pleased to announce that the R.M. Hoffman Company ... our firm, founded in 1916, this is a strategically ... is the kind of professional distributor we need to ...
(Date:6/2/2015)... Orleans, LA (PRWEB) June 02, 2015 ... custom gene synthesis to improve protein expression, announced the ... board includes six executives and entrepreneurs with a broad ... software industries. , The team includes: , Jimmy ... Fund: , Roussel has a background in technology and ...
Breaking Biology Technology:Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3
... New statistics just released reveal that R&D investment in ... in 2008, an increase of 3 percent from 2007, ... Company, a San Francisco based global leader in life ... Equity, Merchant Banking and Media and the Washington DC-based ...
... March 10 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... Annual Health Care Conference on Tuesday, March 17, ... Boston. Daniel M. Bradbury, president and chief executive officer ... presentation and breakout session will be webcast, and a recording ...
... FM53 mask with its ISI developed SCBA systemBALTIMORE, March ... respiratory protection, Avon Protection Systems - a subsidiary of ... for Occupational Safety and Health) approval for its new ... division. The ST53 system combines Avon,s tactical FM53 dual ...
Cached Biology Technology:R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008 2R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008 3Avon Protection Systems Receives NIOSH Approval for ST53 SCBA System 2Avon Protection Systems Receives NIOSH Approval for ST53 SCBA System 3
(Date:6/1/2015)... -- According to a new market research ... (Touch-based & Touchless), Application (Consumer Electronics, Automotive, & Others), ... Global Forecast to 2020", published by MarketsandMarkets, the Gesture ... $23.55 Billion by 2020, at a CAGR of 28.23% ... market data T ables and   86   ...
(Date:6/1/2015)... 1, 2015 According to ... Market by Application (Government, Military & Defense, Healthcare, ... and Security), Technology (Face Recognition, Fingerprint Recognition, Iris ... Recognition, and Others), Function (Contact and Non-Contact) & ... Europe , APAC, Row) - Global ...
(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ... "Facial Recognition Market by Solution, by Software, by ... 2020" report to their offering. ... technology become more efficient and cost effective. This ... investment from the commercial sector. The development of ...
Breaking Biology News(10 mins):Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2
... sulfate supplementation before preterm delivery cuts the risk for ... by University of Alabama at Birmingham (UAB) obstetrician Dwight ... of The New England Journal of Medicine. , ... affecting control of movement and posture and limiting activity. ...
... Genetics, and working in conjunction with Society in ... exploring new avenues in the relationship between science and ... where authorship really matters. Based on a powerful authorship ... to its corresponding author. In this way readers can ...
... A 75-million-year-old fossil of a pregnant turtle and a nest ... southeastern Alberta by scientists and staff from the University of ... ideas on the evolution of egg-laying and reproduction in turtles ... of a pregnant turtle has been found and the description ...
Cached Biology News:Common treatment to delay labor decreases preterm infants' risk for cerebral palsy 2Common treatment to delay labor decreases preterm infants' risk for cerebral palsy 3ETH Zurich-administered fund ends scientific anonymity 2Ancient mother spawns new insight on reptile reproduction 2
... Immunogen: Synthetic peptide derived from the ... 36 protein This peptide sequence is ... another Zymed polyclonal Connexin 36 antibody Cat. ... Connexin 36. Reactivity: Mouse (positive control: ...
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
...
...
Biology Products: